All the latest worldwide HIV and AIDS news, including treatment, prevention, and hepatitis and TB co-infections. News from our own team of writers plus articles we have selected from other sources.

aidsmap hiv & aids news


← First12345...773Next →

hiv & aids news selected from other sources

  • HIV prevention policy
    As EU Approval Moves Closer Are Governments Prepared For PrEP?
    Seeking Alpha | 1 hour ago

    On Friday the EU's Committee for Medicinal Products for Human Use (CHMP) announced its positive opinion on Gilead’s HIV pre-exposure prophylaxis product Truvada PrEP. But with many European governments trying to control healthcare costs, the biggest issue facing Truvada PrEP might not be approval but rather reimbursement.

  • Prince Harry's HIV test inspired a 500% increase in people checking their status, says charity
    Daily Mirror | 1 hour ago

    The Terrence Higgins Trust described the effect of the prince’s social media appeal as a “groundbreaking moment in the fight against HIV ”. The charity was running a pilot scheme offering people the chance to find out their status by sending off for a 15-minute HIV self-testing kit when Harry sat down for his test on Thursday July 14.

  • Prisoners
    Prisoners pose biggest risk for HIV infection rates in the EECA
    University of Bristol | 18 hours ago

    Prisoners are likely to be the primary risk group for HIV infections in Eastern Europe in the next 15 years, researchers from the University of Bristol have found. Their study was published as part of series in the Lancet on HIV and related infections in prisoners, which was also presented at this month's International AIDS Conference in Durban, South Africa.

  • Hepatitis C treatment
    CHMP Grants Positive Opinion for Shorter Treatment Duration with AbbVie's VIEKIRAX® for Patients with Genotype 4 Chronic Hepatitis C with Compensated Cirrhosis (Child-Pugh A)
    Manual Items | 26 July 2016

    AbbVie announced today that the European Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has granted a positive opinion for the use of 12 weeks of VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) with ribavirin (RBV) in genotype 4 (GT4) chronic hepatitis C virus (HCV) infected adult patients with compensated cirrhosis (Child-Pugh A). VIEKIRAX with RBV is currently approved in the European Union for GT4 patients with compensated cirrhosis for 24 weeks.

  • Nutrition
    Vitamin D supplements 'advised for everyone'
    BBC Health | 25 July 2016

    Everyone should consider taking vitamin D supplements in autumn and winter, public health advice in England and Wales says.

  • Achieving the 90-90-90 target
    Implementation of the 2016 Political Declaration on Ending AIDS discussed at International AIDS Conference
    UNAIDS | 25 July 2016

    In June 2016, United Nations Member States committed to implementing a bold agenda to end the AIDS epidemic by 2030 during the United Nations General Assembly High-Level Meeting on Ending AIDS. The progressive, new and actionable Political Declaration includes a set of specific, time-bound targets and actions that must be achieved by 2020 to get on the Fast-Track and end the AIDS epidemic by 2030 within the framework of the Sustainable Development Goals.

  • PrEP
    European CHMP Adopts Positive Opinion on Truvada® for Pre-Exposure Prophylaxis
    Gilead press release | 22 July 2016

    Gilead Sciences, Inc. (Nasdaq:GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), has adopted a positive opinion on the company’s Type II variation application for once-daily Truvada® (emtricitabine 200 mg/tenofovir disoproxil 245 mg) in combination with safer sex practices to reduce the risk of sexually acquired HIV-1 infection among uninfected adults at high risk, a strategy known as pre-exposure prophylaxis, or PrEP.

  • HIV and criminal law
    Global advocacy highlights against HIV criminalisation presented at AIDS 2016
    HIV Justice Network | 22 July 2016

    Yesterday, at the International AIDS Conference in Durban, the HIV Justice Network and GNP+ presented highlights relating to global advocacy against HIV criminalisation based on updated research from our Advancing HIV Justice 2 report.

  • TB treatment
    Daily TB Treatment Better Than Intermittent
    MedPage Today HIV/AIDS | 22 July 2016

    Patients diagnosed with tuberculosis as well as HIV do better in combating tuberculosis with an intensified daily regimen rather than intermittent therapy that delivers less medicine, researchers reported here.

  • How HIV causes disease
    HIV entry mechanism into immune cell nucleus revealed
    HIV / AIDS News From Medical News Today | 22 July 2016

    How does HIV enter the nucleus of immune cells when it is bigger than the pores in its walls? New research shows it hijacks a protein to enlarge the pores.

← First12345...1217Next →

Conference news

News from the ASM Microbe conference in Boston.

HIV update

Sign up for HIV update, our fortnightly news bulletin for people living with HIV in the UK.

Achieving the 90-90-90 target

With advances in HIV testing, treatment and care, some countries are making great progress towards the UNAIDS 90-90-90 target.

aidsmap news apps

Download the free aidsmap news iPhone and android apps.

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap